February 5, 2025
Source: drugdu
183
On January 27, Tianyu shares (300702) issued an announcement that the company's Avatrombopag maleate API recently passed the review of the National Drug Administration Drug Review Center (CDE). The API belongs to Class 4 chemical drugs, with a registration number of Y20230000333, and the review result and the preparation are jointly reviewed as A.
The company submitted a registration application for Avatrombopag maleate API to CDE in June 2023 and was accepted. Although the API has passed the CDE review, it still needs to obtain the "compliance" result of the GMP compliance inspection of the Zhejiang Provincial Drug Administration before it can be marketed in China. At present, there are 14 manufacturers in China that have passed the CDE technical review. The company is preparing to apply for a GMP compliance inspection. There is still uncertainty about the time of listing and sales. Investors are reminded to make prudent decisions and pay attention to investment risks.
In the first three quarters of 2024, Tianyu shares achieved revenue of 1.932 billion yuan and net profit attributable to shareholders of the parent company of 85.11 million yuan.
Source: https://finance.eastmoney.com/
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.